Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases
Abstract Background Azvudine and nirmatrelvir/ritonavir are recommended as priority treatments for SARS-CoV-2 infection in China, but their effectiveness and safety in patients with pre-existing chronic liver diseases remains unknown. Methods We conducted a multicenter retrospective cohort study of...
Saved in:
| Main Authors: | Guanyue Su, Feng Gao, Mengzhao Yang, Ling Wang, Lili Liang, Silin Li, Guangming Li, Na Han, Guotao Li, Guowu Qian, Shixi Zhang, Hong Luo, Donghua Zhang, Hongxia Liang, Zhigang Ren |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Virology Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12985-025-02771-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A retrospective cohort study of the efficacy and safety of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients aged over 60 years
by: Bo Yu, et al.
Published: (2025-03-01) -
Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19
by: Bohan Jia, et al.
Published: (2025-03-01) -
Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study
by: Wei Yang, et al.
Published: (2024-12-01) -
Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19
by: Jin Yang, et al.
Published: (2025-05-01) -
Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes
by: Guanyue Su, et al.
Published: (2025-02-01)